TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2011 - 2026)
TherapeuticsMD's (TXMD) quarterly Depreciation & Amortization (CF) came in at $95000.0 in Q2 2026, down 1.04% on a YoY basis from $96000.0 in Q2 2025, and up 1.06% quarter-over-quarter from $94000.0 in Q1 2026.
Powered by 
Analysis
TherapeuticsMD (TXMD) Depreciation & Amortization (CF) (2011 - 2026) Analysis & Trends
TherapeuticsMD (TXMD) has reported Depreciation & Amortization (CF) for 9 consecutive years, with $95000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Depreciation & Amortization (CF) fell 1.04% year-over-year to $95000.0; the trailing twelve-month figure through Jun 2026 stood at $382000.0 (down 1.29% YoY), and the FY2025 full-year result was $384000.0, down 24.56% from the prior year.
- Depreciation & Amortization (CF) grew to $95000.0 in Q2 2026 per TXMD's latest filing, from $94000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $637000.0 in Q4 2023 and bottomed at $27000.0 in Q1 2023.
- Historically, Depreciation & Amortization (CF) has averaged $177666.7 across 5 years, with a median of $114500.0 in 2023.
- The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) slumped 91.79% in 2023, then soared 392.59% in 2024.
- Over 5 years, Depreciation & Amortization (CF) stood at $309000.0 in 2022, then surged by 106.15% to $637000.0 in 2023, then tumbled by 84.3% to $100000.0 in 2024, then declined by 3.0% to $97000.0 in 2025, then fell by 2.06% to $95000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $95000.0, $94000.0, and $97000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 650.65 Bn | 629.89 Bn | 17.26 Bn | 1.96 Bn |
| 2 | AbbVie | 466.34 Bn | 459.82 Bn | 12.70 Bn | - |
| 3 | Merck | 362.11 Bn | 355.02 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 267.81 Bn | 260.52 Bn | 11.24 Bn | - |
| 5 | Pfizer | 157.31 Bn | 145.91 Bn | 10.94 Bn | 1.62 Bn |
| 6 | Bristol Myers Squibb | 128.75 Bn | 117.69 Bn | 9.25 Bn | 594.00 Mn |
| 7 | Sanofi | 51.80 Bn | 44.84 Bn | 10.79 Bn | 3.97 Bn |
| 8 | Revolution Medicines | 40.91 Bn | 40.91 Bn | - | - |
| 9 | BeOne Medicines | 39.65 Bn | 34.55 Bn | 1.53 Bn | 40.52 Mn |
| 10 | TherapeuticsMD | 25.35 Mn | 16.16 Mn | - | 95,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 95,000.00 |
| Mar 31, 2026 | 94,000.00 |
| Dec 31, 2025 | 97,000.00 |
| Sep 30, 2025 | 96,000.00 |
| Jun 30, 2025 | 96,000.00 |
| Mar 31, 2025 | 95,000.00 |
| Dec 31, 2024 | 100,000.00 |
| Sep 30, 2024 | 96,000.00 |
| Jun 30, 2024 | 180,000.00 |
| Mar 31, 2024 | 133,000.00 |
| Dec 31, 2023 | 637,000.00 |
| Sep 30, 2023 | 130,000.00 |
| Jun 30, 2023 | 129,000.00 |
| Mar 31, 2023 | 27,000.00 |
| Dec 31, 2022 | 309,000.00 |
| Sep 30, 2022 | 273,000.00 |
| Jun 30, 2022 | 282,000.00 |
| Mar 31, 2022 | 329,000.00 |
| Dec 31, 2021 | -2.36 Mn |
| Sep 30, 2021 | 1.03 Mn |